Overview: Deoxypyridinoline (DPD) TestIntroduction: The Deoxypyridinoline (DPD) Test measures bone turnover markers to assess osteoporosis or bone disease, causing bone pain or fractures. Aligned with 2023 NOF guidelines, it uses an immunoassay for high sensitivity, aiding in bone health screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in clinical pathology for patients with suspected bone disorders.
Other Names: DPD Crosslinks Assay, Bone Turnover Test.
FDA Status: Laboratory-developed test (LDT), meeting clinical pathology standards for diagnostic accuracy.
Historical Milestone: DPD testing began in the 1990s with bone metabolism research. Immunoassays emerged in the 2000s, improving accuracy for bone turnover assessment.
Purpose: Diagnoses osteoporosis or bone disease, guides treatment, and monitors bone turnover in patients with bone pain or fractures.
Test Parameters: 1. Deoxypyridinoline
Pretest Condition: Fasting for 10-12 hours required. Collect 24-hour urine sample. Report symptoms like bone pain or fractures, and list medications like bisphosphonates.
Specimen: 50-100 mL urine (24-hour collection, sterile container). Transport in a biohazard bag within 2 hours.
Sample Stability at Room Temperature: 2 hours
Sample Stability at Refrigeration: 24 hours
Sample Stability at Frozen: Not frozen
Medical History: Document bone pain, fractures, or history of osteoporosis. Include current medications, especially bone health drugs.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for bone therapy.
Procedural Considerations: Uses an immunoassay to measure DPD levels. Results are available in 3-5 days, enabling clinical decisions.
Factors Affecting Result Accuracy: Incomplete urine collection or medications can affect results. Contamination may reduce accuracy.
Clinical Significance: Elevated DPD levels indicate increased bone turnover, suggesting osteoporosis or bone disease. Normal levels may require further testing.
Specialist Consultation: Consult an endocrinologist or rheumatologist for result interpretation.
Additional Supporting Tests: Bone density scan, calcium levels, or vitamin D test to confirm bone health status.
Test Limitations: Results may be affected by medications or incomplete collection. Clinical correlation is required.
References: NOF Osteoporosis Guidelines, 2023; Journal of Bone and Mineral Research, Eastell R, 2022.
